Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Is now the time to buy Biogen? Find out by accessing our full research report, it’s free.
Biogen (BIIB) Q2 CY2026 Highlights:
- Revenue: $2.74 billion vs analyst estimates of $2.44 billion (3.4% year-on-year growth, 12.1% beat)
- Adjusted EPS: $3.60 vs analyst estimates of $2.05 (75.8% beat)
- Management raised its full-year Adjusted EPS guidance to $16.35 at the midpoint, a 10.8% increase
- Free Cash Flow Margin: 17.9%, up from 5.1% in the same quarter last year
- Market Capitalization: $30.36 billion
Company Overview
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Revenue Growth
A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Biogen’s demand was weak over the last five years as its sales fell at a 3% annual rate. This was below our standards and is a sign of lacking business quality.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Biogen’s annualized revenue growth of 1.8% over the last two years is above its five-year trend, which is encouraging. 
This quarter, Biogen reported modest year-on-year revenue growth of 3.4% but beat Wall Street’s estimates by 12.1%.
Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a slight deceleration versus the last two years. This projection is underwhelming and implies its products and services will face some demand challenges.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Operating Margin
Biogen has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 23.1%.
Looking at the trend in its profitability, Biogen’s operating margin decreased by 9.9 percentage points over the last five years. Even though its historical margin was healthy, shareholders will want to see Biogen become more profitable in the future.
in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Sadly for Biogen, its EPS declined by 10.6% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.
Diving into the nuances of Biogen’s earnings can give us a better understanding of its performance. As we mentioned earlier, Biogen’s operating margin declined by 9.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Biogen reported adjusted EPS of $3.60, down from $5.47 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Biogen’s full-year EPS to stay about the same, moving from $13.97 to $13.92.
Key Takeaways from Biogen’s Q2 Results
It was good to see Biogen beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a solid print. The stock traded up 1.2% to $208.14 immediately following the results.
Biogen put up rock-solid earnings, but one quarter doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).